T3D Therapeutics is pioneering a novel approach to treating Alzheimer’s disease and other neurodegenerative disorders by focusing on the underlying metabolic dysfunctions that contribute to these conditions. Their lead product candidate, T3D-959, is designed to address the critical issues of energy and lipid metabolism in the brain, which are believed to lead to neurodegeneration. T3D-959 operates by activating two key nuclear receptors, PPAR delta and PPAR gamma, which play essential roles in regulating glucose and lipid metabolism. This dual activation is intended to restore metabolic homeostasis in the brain, potentially reversing the cognitive and motor function deficits associated with Alzheimer’s disease.

The efficacy of T3D-959 has been supported by both preclinical and clinical studies. In preclinical models, T3D-959 demonstrated the ability to reduce neuropathological markers of Alzheimer’s disease, while Phase 1 and Phase 2a clinical trials indicated a favorable safety profile and potential improvements in cognition and motor function among participants. The ongoing PIONEER study aims to further evaluate the drug's safety and efficacy in a larger, randomized, double-blind, placebo-controlled setting. Additionally, T3D-959's mechanism of action shows promise for application in other neurodegenerative diseases, such as Huntington’s disease, highlighting its potential as a transformative therapy in the field of neurodegenerative disease treatment.

United States

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 and has initiated pre-clinical studies in Huntington’s Disease models.

T3D Therapeutics

Company Details